Drazen Ostovic

US Patent:

6645961, Nov 11, 2003

Filed:

Mar 4, 1998

Appl. No.:

09/045885

Inventors:

Chung Y. Lui - Lansdale PA
Drazen Ostovic - Lansdale PA
Ashok V. Katdare - Norristown PA
Christine Stelmach - Tinton Falls NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 31535

US Classification:

5142315, 514252, 514255, 514311

Abstract:

This invention relates to a dry granulation capsule formulation of the HIV protease inhibitor, indinavir sulfate, which is useful in the treatment of AIDS, ARC or HIV infection. Processes for making the oral formulation are also disclosed.

US Patent:

2005016, Jul 28, 2005

Filed:

Mar 13, 2003

Appl. No.:

10/509213

Inventors:

Sandra Robertson - Harleysville PA,
Maria Cruanes - Lansdale PA,
Sami karaborni - Lansdale PA,
Drazen Ostovic - Newbury Park CA,
Ashkan Kamali - Ask West Conshohacken PA,
Santipharp Panmai - North Wales PA,

International Classification:

A61K031/541
A61K031/5377
A61K031/496
A61K031/4745
A61K009/48
A61K009/20

US Classification:

514210210, 514233800, 514300000, 514227800, 514253040, 424451000, 424464000

Abstract:

Pharmaceutical compositions comprise a therapeutically effective amount of an 8-hydroxy-1,6-naphthyridine-7-carboxamide of Formula (I), or a pharmaceutically acceptable salt thereof: and a nonionic surfactant; wherein R, R, Rand Qare defined herein. Compounds of Formula (I) are HIV integrase inhibitors, and the pharmaceutical compositions are useful for preventing or treating HIV infection or for preventing, treating, or delaying the onset of AIDS. The pharmaceutical compositions are typically administered orally, for example, in the form of capsules or tablets, and can provide good oral bioavailability. Methods for preparing encapsulated and tabletted forms of the pharmaceutical compositions are described.

US Patent:

2006001, Jan 26, 2006

Filed:

Jul 7, 2005

Appl. No.:

11/176610

Inventors:

David Boardman - Norristown PA,
Shyam Karki - Lansdale PA,
Aquiles Leyes - Schwenksville PA,
Drazen Ostovic - Newbury Park CA,

International Classification:

A61K 31/59

US Classification:

514167000

Abstract:

This invention is related to a process for preparing a stabilized form of vitamin D which comprises the steps of: a) dissolving vitamin D in a solution that contains water and at least one surfactant to produce a mixture; b) spraying the mixture onto an inert carrier to produce a wet mass; and c) drying the wet mass obtain the stabilized form of vitamin D.

US Patent:

2007029, Dec 27, 2007

Filed:

Nov 18, 2005

Appl. No.:

11/667344

Inventors:

Andrey Peresypkin - Cranford NJ,
Eleni Dokou - Harleysville PA,
Craig McKelvey - Ambler PA,
Charles DeLuca - Royersford PA,
Laman Alani - Lansdale PA,
Todd Gibson - North Haven CT,
Danielle Euler - Souderton PA,
Santipharp Panmai - West Point PA,
W. Wuelfing - Schwenksville PA,
Thomas Gandek - Collegeville PA,
Drazen Ostovic - Newbury Park CA,
Timothy Rhodes - South Orange NJ,
Brian Hamilton - Lansdale PA,

International Classification:

A61K 9/48
A61K 31/44
A61P 25/30
A61P 3/04
A61P 3/10

US Classification:

424456000, 514351000

Abstract:

N-[1S,2S]-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-trifluoromethyl]pyridine-2-yl}oxy}propanamide (Compound I) has surprisingly improved solubility and bioavailability in a lipophilic vehicle comprising a pharmaceutically acceptable digestible oil, a surfactant, or a cosolvent, or a mixture of any two or more thereof. In one embodiment of the present invention are self-emulsifying or self-microemulsifying composition comprising 1) Compound I; 2) a surfactant having an HLB of 1 to 8; and 3) a surfactant having an HLB of over 8 to 20; and optionally, 4) a digestible oil and/or cosolvent and/or antioxidant or preservative.

US Patent:

2008005, Feb 28, 2008

Filed:

Aug 22, 2007

Appl. No.:

11/895071

Inventors:

Annette Bak - Watertown MA,
Drazen Ostovic - Newbury Park CA,

International Classification:

A61K 31/19
C07C 57/03
C07C 57/10

US Classification:

514557, 562598, 562601

Abstract:

The present invention relates to a pharmaceutical co-crystal comprising an active pharmaceutical ingredient and a co-crystal agent having the structure R—C(═O)XH.

US Patent:

6008207, Dec 28, 1999

Filed:

Aug 13, 1998

Appl. No.:

9/133200

Inventors:

Gerald S. Brenner - Norristown PA
Drazen Ostovic - Lansdale PA
Earl R. Oberholtzer - Hatfield PA
J. Eric Thies - Scotch Plains NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3166

US Classification:

514108

Abstract:

Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical doage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient.

US Patent:

5849726, Dec 15, 1998

Filed:

Dec 3, 1997

Appl. No.:

8/973386

Inventors:

Gerald S. Brenner - Norristown PA
Drazen Ostovic - Lansdale PA
Earl R. Oberholtzer - Hatfield PA
J. Eric Thies - Scotch Plains NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3166

US Classification:

514108

Abstract:

Disclosed is a method for treating and preventing bone loss in patients by administering a formulation of anhydrous alendronate sodium. Also described is a pharmaceutical dosage form of said anhydrous alendronate sodium, being anhydrous 4-amino-1-hydroxy-butylidene-1,1-bisphosphonic acid, monosodium salt, in a pharmaceutically acceptable excipient.